Scancell Holdings (GB:SCLP) has released an update.
Scancell Holdings has reported a successful year with its lead cancer vaccine SCIB1 showing promising results in a Phase 2 trial for melanoma, exceeding the 70% objective response rate target, while also progressing with its Modi-1 vaccine and securing strategic partnerships. The company’s financial position remains solid with an operating loss of £18.3 million, a cash balance of £14.8 million, and a cash runway extending into the third quarter of 2025. Key organizational appointments have been made, positioning Scancell for pivotal studies and further development in the coming years.
For further insights into GB:SCLP stock, check out TipRanks’ Stock Analysis page.
